Quality of life in patients with ischemic heart disease and heart failure

О.J. Zharinov, N.B. Іvaniuk, О.А. Epanchintseva, R.M. Vitovsky, B.М. Todurov

References 

1. Baleva ES, Aleshkina OYu. Prospects for the study of the quality of life of patients with ischemic heart disease. Bulletin of Medical Internet Conferences. 2011;1(7):43-44. (in Russ.).
2. Voronkov LG, Lutsak O, Babich PM. Predictors of quality of life in patients with chronic heart failure. Ukrainian Medical Journal. 2011;3(83):86-88. (in Ukr.).
3. Kryukov NN, Kachkovsky MA Influence of heart failure on quality of life of patients with myocardial infarction. Russian Heart Failure Journal. 2005;6(4):169-171. (in Russ.).
4. Libis RA, Kots YaI, Ageev FT. Quality of life as a criterion for the successful therapy of patients with chronic heart failure. Russ. Med. J. 1999;2:84-87. (in Russ.).
5. Yagenskyi AV, Höfer S, Sichkaruk IM, Oldridge N. Quality of life assessment in patients with ischemic heart disease: validation of Ukrainian-language version of MacNew Heart Disease Health-related Quality of Life. Ukrainian Cardiology Journal. 2013;3:22-28. (in Ukr.).
6. Brink E, Grankvist G, Karlson BW, Hallberg LR. Health-related quality of life in women and men one year after acute myocardial infarction. Qual. Life Res. 2005;14(3). Р. 749-757.
7. Chaitman BR, Ryan TJ, Kronmal RA, et al. Coronary Artery Surgery Study (CASS): Comparability of 10 year survival in randomized and randomizable patients. J Am Coll Cardiol. 1990;16(5):1071-1078.
8. Chan PS, Soto G, Jones PG, et al. Patient health status and costs in heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2009;119:398-407.
9. Cleland JG, Calvert M, Freemantle N, et al. The Heart Failure Revascularisation Trial (HEART). Eur J Heart Fail. 2011;13(2):227-233.
10. Cohn JN, Tognoni G. A Randomized Trial Of The Angiotensin-Receptor Blocker Valsartan In Chronic Heart Failure. New Engl J. Med. 2001;345(23):1667-1675.
11. Crilley JG, Farrer M. Impact of first myocardial infarction on self-perceived health status. QJM. 2001;94(1):13-18.
12. Dagenais GR, Lu J, Faxon DP, et al. Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease. Circulation. 2011;123(14):1492-1500.
13. De Quadros AS, Lima TC, Rodrigues AP et al. Quality of life and health status after percutaneous coronary intervention in stable angina patients. Cathet Cardiovasc Intervent. 2011;77:954-960.
14. DeVon HA, Ryan CJ, Ochs AL, et al. Symptoms across the continuum of acute coronary syndromes: differences between women and men. Am J Crit Care. 2008;17(1):14-25.
15. Dougherty CM, Dewhurst T, Nichol WP, et al. Comparison of three quality of life instruments in stable angina pectoris: the Seattle Angina Questionnarie (SAQ), the Short Form Health Survey (SF-36) and the Quality of Life IndexCardiacVersion III (QLI). J Clin Epidemiol 1998;51:569-575.
16. Ekici B, Ercan EA, Cehreli S, et al. The effect of emotional status and health-related quality of life on the severity of coronary artery disease. Kardiologia Polska. 2014;72(7):617-623.
17. Favarato ME, Hueb W, Boden WE, et al. Quality of life in patients with symptomatic multivessel coronary artery disease: A comparative post hoc analyses of medical, angioplasty or surgical strategies - MASS II trial. Int J Cardiol. 2007;116(3):364-370.
18. Filade I, Ramos I. Validity and reliability of the SF-36 Health Survey Questionnaire in patients with coronary artery disease. J Clin Epidemiol. 2000;53:359-365.
19. Graham MM, Norris CM, Galbraith PD, et al. Quality of life after coronary revascularization in the elderly. Eur Heart J. 2006;27:1690-1698.
20. Haddock CK, Poston WSC, Taylor JE, et al. Smoking and health outcomes after percutaneous coronary intervention. Am Heart J. 2003;145(4):652-657.
21. Haerer W, Bauer U, Sultan N, et al. Acute and chronic effects of diuretic monoterapy by Piretanide in congestive heart failure - a placebo-controlled trial. Cardiovasc Drugs Ther. 1990;4:515-522.
22. Hak T, Willems D, van der Wal G, et al. A qualitative validation of the Minnesota Living with Heart Failure Questionnaire. Qual. Life Res. 2004;13:417-426.
23. Henderson RA, Pocock SJ, Clayton TC, et al. Seven-year outcome in the RITA-2 trial: Coronary angioplasty versus medical therapy. J Am Coll Cardiol. 2003;42(7):1161-1170.
24. Hjalmarson A, Goldstein S, Fagerberg B. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: MERIT Heart Failure. JAMA. 2000;283:1295-1302.
25. Hobbs FD, Kenkre JE, Roalfe AK, et al. Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J. 2002;23(23):1867-1876.
26. Hofer S, Lim L, Guyatt G, Oldridge N. The MacNew Heart Disease health-related quality of life instrument: a summary. Health Qual Life Outcomes. 2004;2:3.
27. Hueb WA, Soares PR, Almeida De Oliveira S, et al. Five-year follow-up of the medicine, angioplasty, or surgery study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty, or bypass surgery for single proximal left anterior descending coronary artery stenosis. Circulation. 1999;100:107-113.
28. Jenkinson C, Jenkinson D, Shepperd S. Evaluation of treatment for congestive heart failure in patients aged 60 years and older using generic measures of health status (SF-36 and Coop Charts). Age and Ageing. 1997;26:7-13.
29. Kaul P, Lytle BL, Spertus JA, et al. Influence of racial disparities in procedure use on functional status outcomes among patients with coronary artery disease. Circulation. 2005;111:1284-1290.
30. Kimble LP, McGuireb DB, Dunbara SB. Gender differences in pain characteristics of chronic stable angina and perceived physical limitation in patients with coronary artery disease. NIH Public Access. 2003;101(10):45-53.
31. Kosiborod M, Soto GE, Jones PG, et al. Identifying heart failure patients at high risk for near-term cardiovascular events with serial health status assessments. Circulation. 2007;115:1975-1981.
32. Lee GA. Coronary artery disease and quality of life. Baker IDI Heart and Diabetes Institute. Melbourne, Australia, 2010:1-10.
33. Littik ML, Lesman-Leegte I, Jaarsma T. Quality of life and depressive symptoms in heart failure patients and their partners: the impact of role and gender. J Card. Fail. 2009;15(7):580-585.
34. Mark DB, Knight JD, Velazquez EJ, et al. Quality-of-life outcomes with coronary artery bypass graft surgery in ischemic left ventricular dysfunction: а randomized trial. Ann Intern Med. 2014;161(6):392-399.
35. Marwick TH, Zuchowski C, Lauer MS. Functional status and quality of life in patients with heart failure undergoing coronary bypass surgery after assessment of myocardial viability. J Am Coll Cardiol. 1999;33(3):750-758.
36. Mommersteeg PMC, Denollet J, Spertus JA, et al. Health status as a risk factor in cardiovascular disease: a systematic review of current evidence. Amer Heart J. 2008;10:1-11.
37. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949-3003.
38. Müller K, Gamba G, Jaquet F. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV - efficacy and quality of life. Eu. J Heart Fail. 2003;5(6):793-801.
39. Najafi M, Sheikhvatan M, Montazeri A et al. Quality of life in coronary artery disease: SF-36 compared to WHOQOL-BREF. J Tehran University Heart Center. 2008;3(2):101-106.
40. Nogueira IDB, Servantes DM, Nogueira PA. de MS. Correlation between quality of life and functional capacity in cardiac failure. Arq Bras Cardiol. 2010;95(2):238-243.
41. Norris CM, Saunders LD, Ghali WA, et al. Health-related quality of life outcomes of patients with coronary artery disease treated with cardiac surgery, percutaneous coronary intervention or medical management. Can J Cardiol. 2004;20(12):1259-1266.
42. O’Leary C, Jones P. The left ventricular dysfunction questionnaire (LVD-36): reliability, validity, and responsiveness. Heart. 2000;83(6):634-640.
43. Pelegrino VM, Dantas RAS, Clark AM. Health-related quality of life determinants in outpatients with heart failure, Revista Latino-Americana de Enfermagem. Heart Lung. 2011;19(3):451-457.
44. Pepine CJ. Effects of pharmacologic therapy on health-related quality of life in elderly patients with atrial fibrillation: a systematic review of randomized and nonrandomized trials. Cardiology. 2013;7:1-20.
45. Pettersen KI. Health-related quality of life after myocardial infarction: methods for assessment and determinants. Faculty of Medicine, University of Oslo. 2008;689:1-54.
46. Pfisterer M, Buser P, Osswald S, et al. Trial of Invasive versus Medical therapy in Elderly patients (TIME) Investigators. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. JAMA. 2003;289(9):1117-1123.
47. Poblete PF, Kyle MC, Pipberger HV, et al. Effect of treatment on morbidity in hypertension. veterans administration cooperative study on antihypertensive agents. Effect on the electrocardiogram. Circulation. 1973;48:481-490.
48. Pron G. Coronary Revascularization in Ischemic Heart Failure Patients: a rapid review. Health Quality Ontario. 2013;1:28.
49. Rumsfeld JS, Alexander KP, Goff DCJr, Graham MM. Cardiovascular health: the importance of measuring patient-reported health status: a scientific statement from the American Heart Association. Circulation. 2013;127(22):2233-2249.
50. Rumsfeld JS, MaWhinney S, McCarthy MJr, et al. Health-related quality of life as a predictor of mortality following coronary artery bypass graft surgery. Participants of the Department of Veterans Affairs Cooperative Study Group on Processes, Structures, and Outcomes of Care in Cardiac Surgery. JAMA. 1999;281(14):1298-1303.
51. Sanderson JE, Chan SKW, Yip G. Beta-blockade in heart failure. A comparison of carvedilol with metoprolol. JACC. 1999;34(5):1522-1528.
52. Scarinzi C, Berchialla P, Ghidina M, et al. The Severe Heart Failure Questionnaire: Italian translation and linguistic validation. J. Preventive Medicine and Hygiene. 2008;49(4):152-157.
53. Seki1 S, Kato N, Ito N, et al. Validity and reliability of Seattle Angina Questionnaire japanese version in patients with coronary artery disease. Asian Nursing Research. 2010;4(2):57-63.
54. Spertus JA, Jones P, McDonell M, et al. Health status predicts long-term outcome in outpatients with coronary disease. Circulation. 2002;106:43-49.
55. Spertus JA, Salisbury AC, Jones PG, et al. Predictors of quality-of-life benefit after percutaneous coronary intervention. Circulation. 2004. 110:3789-3794.
56. Spiraki C, Kaitelidou D. Health-related quality of life measurement in patients admitted with coronary heart disease and heart failure to a cardiology department of a secondary urban hospital in Greece. Hellenic J Cardiol. 2008;49:241-247.
57. Taira DA, Seto TB, Ho KKL. Impact of smoking on health-related quality of life after percutaneous coronary revascularization. Circulation. 2000;102:1369-1374.
58. Takiuti ME, Hueb W, Hiscock SB, et al. Quality of life after surgical myocardial revascularization, angioplasty or medical treatment. Arq Bras Cardiol. 2007;88(5):475-481.
59. Tofighi S, Kiadaliri AA, Sadeghifar J, et al. Health-related quality of life among patients with coronary artery disease: a post-treatment follow-up study in Iran. Cardiology Research and Practice. 2012;1-6.
60. Torado JF, Shen BJ, Raffa SD. Prevalence of anxiety disorders in men and women with established coronary heart disease. J Cardiopulmonary Rehabilitation. 2007;27:86-91.
61. Van Jaarsveld CH, Sanderman R, Miedema I, et al. Changes in health-related quality of life in older patients with acute myocardial infarction or congestive heart failure: a prospective study. J Am Geriatr Soc. 2001;49(8):1052-1058.
62. Wadie B, Shaheen S, Nashat E. Quality of life assessment after coronary artery revascularization using coronary revascularization outcome questionnare in ischemic egiptian patients. Med J Cairo Univ. 2013;81(1):1-5.
63. Währborg P, on behalf of the CABRI trialists. Quality of life after coronary angioplasty or bypass surgery. 1-year follow-up in the coronary angioplasty versus bypass revascularization investigation (CABRI) trial. Eur Heart J. 1999;20:653-658.
64. Williams GH. Quality of life and its impact on hypertensive patients. Amer J Med. 1987;82:99-105.
65. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life: a conceptual model of patient outcomes. JAMA. 1995;273(1):59-65.
66. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 2014;46(4):517-592.
67. Yusuf S, Zucker D, Passamani E, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994;344(8922):563-570.
68. Zambroski CH, Moser DK, Bhat G, et al. Impact of symptom prevalence and symptom burden on quality of life in patients with heart failure. Eur J Cardiovasc Nurs. 2005;4(3):198-206.
69. Zellweger MJ, Osterwalder RH, Langewitz W, et al. Coronary artery disease and depression. Eur Heart J. 2004;25:3-9.
70. Zhang Z, Mahoney EM, Stables RH, et al. Disease-specific health status after stent-assisted percutaneous coronary intervention and coronary artery bypass surgery. one-year results from the Stent or Surgery trial. Circulation. 2003;108(14):1694-1700.

Comparative analysis of the impact of glomerular filtration rate on the course of ST-segment elevation myocardial infarction in women and men

N.V. Netyazhenko

References

1. Fricker J. Women’s heart health: the focus of this issue. Eur Нeart J. 2011;32:1301-1310.
2. Inker LA, et al. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD. Amer J Kidney Diseases. 2014;63(5):713-735.
3. Jha V, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260-272.
4. Levey AS, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Іntern Мed. 2003;139(2):137-147.
5. Li C, et al. A Multicentre Prospective Evaluation of the Impact of Renal Insufficiency on In-hospital and Long-term Mortality of Patients with Acute ST-elevation Myocardial Infarction. Chinese Med J. 2015;128(1):1.
6. Łoboz-Grudzień K, Jaroch J. Women with acute coronary syndromes have a worse prognosis - why? The need to reduce ‘treatment-seeking delay’. Cardiology J. 2011;18(3):219-221.
7. Nitsch D, et al. Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. Brit Med. J. 2013;346.
8. Pugliese G, et al. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation provides a better definition of cardiovascular burden associated with CKD than the Modification of Diet in Renal Disease (MDRD) Study formula in subjects with type 2 diabetes. Atherosclerosis.2011;218(1):194-199.
9. Shroff GR, Frederick PD, Herzog CA. Renal failure and acute myocardial infarction: clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial Infarction. Amer Heart J. 2012;163(3):399-406.
10. Van de Werf F, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J. 2008;29(23):2909-2945.
11. Van der Velde M, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney International. 2011;79(12):1341-1352.
12. Washam JB, et al. Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome. A scientific statement from the American Heart Association. Circulation. 2015;131(12):1123-1149.

Switching to warm blood cardioplegia supplemented with magnesium sulfate: what do we gain? Iu.S. Guzgan, V.D. Moscalu, G.G. Manolache

Iu.S. Guzgan, V.D. Moscalu, G.G. Manolache, V.I. Morozan, A.A. Batrinac

References

1. Bezrukov A, Bezrukov B. The basic methods of statistical processing of the results of observations in the field of physiology. Мoskva: Medicina, 1974. 151 p. (in Russ.).
2. Birdi I, Giani D, Bryan A.J. Biochemical markers of myocardial injury during cardiac operations. Ann Thorac Surg. 1997;63:879-884.
3. Braathen B, Tonnesen Th. Cold blood cardioplegia reduces the increase in cardiac enzyme levels compared with cold crystalloid cardioplegia in patients undergoing aortic valve replacement for isolated aortic stenosis. Thorac Cardiovasc Surg. 2010;139:874-880.
4. Bortnov A. Cardioplegia combinată cristaloid-sangvină în operaţiile cu circulaţie extracorporală. Autoreferat dis. d.m. Chişinău, 1995. 16 p.
5. Buckberg GD. Warm versus cold blood cardioplegia: a self-imposed and counterproductive dilemma. Ann Thorac Surg. 1993;56:1007-1010.
6. Casalino S, et al. The efficacy and safety of extending the ischemic time with a modified cardioplegic technique for coronary artery surgery. J Card Surg. 2008;23:444-449.
7. Criesmacher A, Grinm M, Schreiner W, et al. Diagnosis of perioperative myocardial infarction by considering relationship of postoperative electrocardiogram charyes and enzyme increases after coronary bypass operations. Clin Chem. 1990;36:883-887.
8. Fan Y, Zhang A, Xiao Y, Hetzer R. Warm versus cold cardioplegia for heart surgery: a meta-analysis. Eur J Card Thorac Surg. 2010;37:912-919.
9. Guru V, Omura J, Alghamdi A, et al. Is blood superior to crystalloid cardioplegia? A meta-analysis of randomized clinical trials. Circulation. 2006;114 (Suppl. 1):331-338.
10. Jacob S, Kallicourdis A, Sellke F, Dunning V. Is blood cardioplegia superior to crystalloid cardioplegia? Interact Cardiovasc Thorac. Surg. 2008;7:491-498.
11. Melrose D, Dreyer B, Bentall H, et al. Elective cardiac arrest. Lancet. 1955;2:21-29.
12. Mentzer R, Tahania M, Lesley R. Myocardial protection in Cardiac Surgery in the adult. N.Y.: McGraw-Hill,2008:443-464.
13. Minatoya K, Okabazashi H, Shimada I, et al. Intermittent antegrade warm blood cardioplegia for CABG: Extending interval of cardioplegia. Ann Thorac Surg. 2000.Vol. 69:74-76.
14. Robinson LA, Schwarz GD, Goddard DB, et al. Myocardial protection for Acquired Heart Disease Surgery: Results of a national survey. Ann Thorac Surg. 1995;59:361-372.
15. Sirvinskas E, et al. Myocardial protective effect of warm blood, tepid blood, and cold crystalloid cardioplegia in coronary artery bypass grafting surgery. Croat Med V. 2005;46:879-888.

Contemporary methods of diagnosis and predicting results of the surgical treatment of aortic stenosis

B.M. Todurov, N.V. Ponych, O.A. Epanchitseva, О.J. Zharinov

References

1. Baumgartner H, Hung J, Bermejo J. EAE/ASE recommendations on echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J Echocardiography. 2009;10:1-25.
2. Blais C, Burwash IG, Mundigler G. et al. Projected valve area at normal flow rate improves the assessment of stenosis severity in patients with low-flow, low-gradient aortic stenosis. The Multicenter TOPAS (Truly or Pseudo-Severe Aortic Stenosis) Study. Circulation. 2006;113:711-721.
3. Brown J, Jenkins C, Marwick TH. Use of myocardial strain to assess global left ventricular function: a comparison with cardiac magnetic resonance and 3-dimensional echocardiography. Am Heart J. 2009;157:102-105.
4. Brown ML, Pellikka PA, Schaff HV. et al. The benefits of early valve replacement in asymptomatic patients with severe aortic stenosis. J Thorac Cardiovasc Surg. 2008;135:308-315.
5. Bruch C, Stypmann J, Gradaus R. et al. Tissue Doppler imaging in patients with moderate to severe aortic valve stenosis: Clinical usefulness and diagnostic accuracy. Am Heart J. 2004;148:696-702.
6. Carabello BA, Paulus WJ. Aortic stenosis. Lancet. 2009;373:956-966.
7. Carroll JD, Carroll EP, Feldman T. et al. Sex-associated differences in left ventricular function in aorticstenosis of the elderly. Circulation.1992;86:1099-1107.
8. Chambers JB. Aortic stenosis. Eur J Echocardiography. 2009;10:111-119.
9. Clavel MA, Burwash IG, Mundigler G, Dumesnil JG. Validation of conventional and simplified methods to calculate projected valve area at normal flow rate in patients with low flow, low gradient aortic stenosis: the multicenter TOPAS (True or Pseudo Severe Aortic Stenosis) study. J Am Soc Echocardiogr. 2010;23 (4):380-386.
10. Collinson J, Henein M, Flather M. et al. Valve replacement for aortic stenosis in patients with poor left ventricular function: comparison of early changes with stented and steintless valve. Circulation. 1999;100 (Suppl II):111-115.
11. Connolly HM, Oh JK, Schaff HV. et al. Severe aortic stenosis with low transvalvular gradient and severe left ventricular dysfunction: result of aortic valve replacement in 52 patients. Circulation. 2000;101:1940-1946.
12. Dandel M, Dworatzek E, Regression of myocardial hypertrophy after aortic valve replacement: faster in women? Circulation. 2010;122:S23-S28.
13. DeFilippi CR, Willett DL, Brickner ME. et al. Usefulness of dobutamine echocardiography in distinguishing severe from nonsevere valvular aortic stenosis in patients with depressed left ventricular function and low transvalvular gradient. Am J Cardiol. 1995;75:191-194.
14. Delgado V, Tops LF, van Bommel RJ. et al. Strain analysis in patients with severe aortic stenosis and preserved left ventricular ejection fraction undergoing surgical valve replacement. Eur Heart J. 2009;30:3037-3047.
15. Douglas PS, Otto CM, Mickel MC. et al. Gender differences in left ventricle geometry and function in patients undergoing balloon dilatation of the aortic valve for isolated aortic stenosis: NHLBI Balloon Valvuloplasty Registry. Br Heart J. 1995;73:548-554.
16. Drazner MH, Rame JE, Marino EK. et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol. 2004;43:2207-2215.
17. Duarte IG, Murphy CO, Kosinski AS. et al. Late survival after valve operation in patients with left ventricular dysfunction. Ann Thor Surg. 1997;64:4:1089-1095.
18. Eichinger WB, Botzenhardt F, Gunzinger R. et al. Left ventricular mass regression after aortic valve replacement with the mosaic bioprosthesis. J. Heart Valve Dis. 2002;11:529-536.
19. Faggiano P, Antonini-Canterin F, Ribichini F. et al. Pulmonary artery hypertension in adult patients with symptomatic valvular aortic stenosis. Am J Cardiol. 2000;85:204-208.
20. Fliegner D, Schubert C, Penkalla A. et al. Female sex and estrogen receptor attenuate cardiac remodeling and apoptosis in pressure overload. Am J Physiol Regul Integr Comp Physiol. 2010;298:R1597-R1606.
21. Flores-Marín A, Gómez-Doblas J. et al. Long-Term Predictors of Mortality and Functional Recovery After Aortic Valve Replacement for Severe Aortic Stenosis With Left Ventricular Dysfunction. Rev Esp Cardiol. 2010;63 (1):36-45.
22. Franke A, Kühl HP. Diagnosis and assessment of severity of aortic valve stenosis. Herz. 2006;31:856.
23. Gaudino M, Alessandrini F. et al. Survival after aortic valve replacement for aortic stenosis: does left ventricular mass regression have a clinical correlate?. Eur. Heart J. 2005;26:51-57.
24. Gjertsson P. et al. Left ventricular diastolic dysfunction late after aortic valve replacement in patients with aortic stenosis. Amer J Cardiology. 2005;96:722-727.
25. Goland S, Trento A, Iida K. et al. Assessment of aortic stenosis by three-dimensional echocardiography: an accurate and novel approach. Heart. 2007. 93:801-807.
26. Iung B, Baron G, Butchart E.G. et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003;24(13):1231-1243.
27. Jacobs LD, Salgo IS, Goonewardena S. et al. Rapid online quantification of left ventricular volume from real-time three-dimensional echocardiographic data. Eur Heart J. 2006;27:460-468.
28. Jander N, Minners J, Holme I. et al. Outcome of patients with low-gradient ‘severe’ aortic stenosis and preserved ejection fraction. Circulation. 2011;123:887-895.
29. Kang DH, Park SJ, Rim JH. et al. Early surgery versus conventional treatment in asymptomatic very severe aortic stenosis. Circulation. 2010;121. 1502-1509.
30. Katholi R, Daniel M. et al. Left Ventricular Hypertrophy: Major Risk Factor in Patients with Hypertension: Update and Practical Clinical Applications. Intern J Hypertension. 2011;1:10.
31. Kapoor N, Varadarajan P, Pai RG. Echocardiographic predictors of pulmonary hypertension in patients with severe aortic stenosis. Eur J Echocardiography. 2008;9:31-33.
32. Kuhl HP, Schreckenberg M, Rulands D. et al. High-resolution transthoracic real-time three-dimensional echocardiography. J Am Coll Cardiol. 2004;43:2083-2090.
33. Lang RM, Mor-Avi V, Sugeng L. et al. Threedimensional echocardiography: the benefits of the additional dimension. J Am Coll Cardiol. 2006;48:2053-2069.
34. Lester SJ, Heilbron B, Gin K. et al. The natural history and rate of progression of aortic stenosis. Chest. 1998;113:1109-1114.
35. Levy F, Laurent M, Monin JL. et al. Aortic valve replacement for low-flow/low-gradient aortic stenosis operative risk stratification and long-term outcome: a European multicenter study. J Am Coll Cardiol. 2008;51:1466-1472.
36. Lung B, Baron G, Tornos P. et al. Valvular heart disease in the community: a European experience. Curr Probl Cardiol. 2007;32:609-661.
37. Lund O, Flo S, Jensen FT. et al. Left ventricular systolic and diastolic function in aortic stenosis. Prognostic value after valve replacement and underlying mechanisms. Eur Heart J. 1997;18 (12):1977-1987.
38. Mancini GB, Dahlof B, Díez J. Surrogate markers for cardiovascular disease: structural markers. Circulation. 2004;109:IV22-IV30.
39. Manovel A, Dawson D, Smith B, Nihoyannopoulos P. Assessment of left ventricular function by different speckle-tracking software. Eur J Echocardiogr. 2010;11:417-421.
40. Marwick TH, Leano RL, Brown J. et al. Myocardial strain measurement with 2-dimensional speckle-tracking echocardiography: definition of normal range. JACC Cardiovasc Imaging. 2009;2:80-84.
41. McCarthy PM. Aortic valve surgery in patients with left ventricular dysfunction. Semin Thorac Cardiovasc Surg. 2002;14:137-143.
42. Minners J, Allgeier M, Gohlke-Baerwolf C. et al. Inconsistencies of echocardiographic criteria for grading of aortic valve stenosis. Eur Heart J. 2008;29:1043-1048.
43. Monin JL, Quere JP, Monchi M. et al. Low-gradient aortic stenosis: operative risk stratification and predictors for long-term outcome: a multicenter study using dobutamine stress hemodynamics. Circulation. 2003;108:319-324.
44. Morena G, Saura D, Oliva MJ. et al. Real-time three-dimensional transesophageal echocardiography in the assessment of aortic valve stenosis. Eur. J. Echocardiogr. 2010;11:9-13.
45. Mor-Avi V, Lang M. Current and Evolving Echocardiographic Techniques for the Quantitative Evaluation of Cardiac Mechanics: ASE/EAE Consensus Statement on Methodology and Indications Endorsed by the Japanese Society of Echocardiography. J Am Soc Echocardiogr. 2011;24:277-313.
46. Mor-Avi V, Sugeng L, Lang RM. Real-time 3-dimensional echocardiography: an integral component of the routine echocardiographic examination in adult patients? Circulation. 2009;119:314-329.
47. Nakai H, Takeuchi M, Yoshitani H. et al. Pitfalls of anatomical aortic valve area measurements using two-dimensional transoesophageal echocardiography and the potential of three-dimensional transoesophageal echocardiography. Eur J Echocardiography. 2010;11:369-376.
48. Nagueh S, Appleto C. et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009;10:165-193.
49. Nishimura RA, Grantham JA, Connolly HM. et al. Low-output, low-gradient aortic stenosis in patients with depressed left ventricular systolic function: the clinical utility of the dobutamine challenge in the catheterization laboratory. Circulation. 2002;106:809-813.
50. Nishimura RA. et al. AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease. Circulation. 2014;129:27-46.
51. Nkomo VT, Gardin JM, Skelton TN. et al. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005-1011.
52. Novaro CM, Katz R, Gottdiener JS. et al. Clinical factors but not C reactive protein predict progression of calcific aortic valve disease: The Cardiovascular Health Study. J Am Coll Cardiol. 2007;50:1992-1998.
53. Osnabrugge RL, Mylotte D, Head SJ. et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-ana lysis and modeling study. J Am Coll Cardiol. 2013;62:1002-1012.
54. Pai R, Varadarajan P, Kapoor N, Bansal R. Aortic Valve Replacement Improves Survival in Severe Aortic Stenosis Associated With Severe Pulmonary Hypertension. Ann Thorac Surg. 2007;84:80-86.
55. Pereira JJ, Lauer MS, Bashir M. et al. Survival after aortic valve replacement for severe aortic stenosis with low transvalvular gradients and severe left ventricular dysfunction. J Am Coll Cardiol. 2002;39:1356-1363.
56. Płońska-Gościniak E, Lipiec P, Lancellotti P. Prognostic value of low-dose dobutamine stress echocardiography in patients with aortic stenosis and impaired left ventricular function. Arch Med Sci. 2013;9:434-439.
57. Quere JP, Monin JL, Levy F. et al. Influence of preoperative left ventricular contractile reserve on postoperative ejection fraction in low-gradient aortic stenosis. Circulation. 2006;113:1738-1744.
58. Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid and tricuspid aortic valves i adults having isolated aortic valve replacement for aortic stenosis with or without associated aortic regurgitation. Circulation. 2005;111:920-925.
59. Schattke S, Baldenhofer G. Acute regional improvement of myocardial function after interventional transfemoral aortic valve replacement in aortic stenosis: A speckle tracking echocardiography study. Cardiovasc Ultrasound. 2012;10:15.
60. Stewart BF, Siscovick D, Lind BK. et al. Clinical factors associated with calcific aortic valve disease: Cardiovascular Health Study. J Am Coll Cardiol. 1997;29:6304.
61. Sugeng L, Shernan SK, Salgo IS. et al. Live 3-dimensional transesophageal echocardiography initial experience using the fully-sampled matrix array probe. J Am Coll Cardiol. 2008;52:446-449.
62. Sutton MSJ, Plappert T, Speigel A. et al. Early postoperative changes in left ventricular chamber size, architecture, and function in aortic stenosis and aortic regurgitation and their relation to intraoperative changes in afterload: a prospective two-dimensional echocardiographic study. Circulation. 1987;76:77-89.
63. Takeda S, Rimington H, Smeeton N, Chambers J. Long axis excursion in aortic stenosis. Heart. 2001;86:52-56.
64. Tribouilloy C, Le´vy F, Rusinaru D, Gue´ret P. et al. Outcome after aortic valve replacement for low-flow/low-gradient aortic stenosis without contractile reserve on dobutamine stress echocardiography. J Am Coll Cardiol. 2009;53:1865-1873.
65. Vahanian A, Alfieri O. et al. Guidelines on the management of valvular heart disease (version 2012) The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardio-Thoracic Surgery. 2012;42:S12-S18.
66. Villari B, Campbell SE, Schneider J. et al. Sex-dependent differences in left ventricular function and structure in chronic pressure overload. Eur Heart J. 1995;16:1410-1419.
67. Witt H, Schubert C, Jaekel J. et al. Sexspecific pathways in early cardiac response to pressure overload in mice. J Mol Med. 2008;86:1013-1024.

Secondary prevention after coronary artery bypass graft surgery

M.Т. Vatutin, A.M. Shevelok, Ye.V. Yeshchenko, Yu.P. Gritsenko, V.A. Karapysh, V.S. Kolesnikov, M.I. Zinkovych, A.M. Zagoruiko, G.E. Degtiarova, M.O. Khrystychenko, Ye.V. Kartamysheva

References 

1. Vatutin NT. Emergency cardiology. Donetsk, 2011. 232 p. (in Russ.).
2. Vatutin NT, Shevelek AN, Degtyareva AE, Kasem SS. The role of hyperaldosteronism and the prospects for the use of aldosterone antagonists. Journal of the National Academy of Medical Sciences of Ukraine. 2014;20(1):43-52. (in Russ.).
3. Shevelok AM. Atrial fibrillation. Donetsk: Kashtan, 2015. 164 p. (in Ukr.).
4. ACCORD Study Group. Ginsberg H.N, Elam M.B, Lovato L.C, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. New Engl J Med. 2010;362:1563-1574.
5. Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol. 2007;50:563-572.
6. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. New Engl J Med. 2007;357:1301-1310.
7. Batsis JA, Romero-Corral A, Collazo-Clavell ML, et al. Effect of weight loss on predicted cardiovascular risk: change in cardiac risk after bariatric surgery. Obesity (Silver Spring). 2007;15:772-784.
8. Bednar F, Osmancik P, Vanek T, et al. Platelet activity and aspirin efficacy after off-pump compared with on-pump coronary artery bypass surgery: results from the prospective randomized trial PRAGUE 11-Coronary Artery Bypass and REactivity of Thrombocytes (CABARET). J Thorac Cardiovasc Surg. 2008;136:1054-1060.
9. Bednar F, Tencer T, Plasil P, et al. Evaluation of aspirin’s effect on platelet function early after coronary artery bypass grafting. J Cardiothorac Vasc Anesth. 2012;26:575-580.
10. Bigger JTJr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery: Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. New Engl. J Med. 1997;337:1569-1575.
11. Brilakis ES, de Lemos JA, Cannon CP, et al. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). Am J Cardiol. 2008;102:552-558.
12. Brinkman WT, Herbert MA, Prince SL, et al. Preoperative betablocker usage: is it really worthy of being a quality indicator? Ann Thorac Surg. 2011;92:788-795.
13. Carrier M, Cossette M, Pellerin M, et al. Statin treatment equalizes long-term survival between patients with single and bilateral internal thoracic artery grafts. Ann Thorac Surg. 2009;88:789-795.
14. Coleman CI, Lucek DM, Hammond J, White CM. Preoperative statins and infectious complications following cardiac surgery. Curr Med Res Opin. 2007;23:1783-1790.
15. David JL, Limet R. Antiplatelet activity of clopidogrel in coronary artery bypass graft surgery patients. Thromb Haemost. 1999;82:1417-1421.
16. De Leon N, Jackevicius CA. Use of aspirin and clopidogrel after coronary artery bypass graft surgery. Ann Pharmacother. 2012;46:678-687.
17. Deo SV, Dunlay SM, Shah IK, et al. Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis. J Card Surg. 2013;28:109-116.
18. Dereli Y, Ege E, Kurban S, et al. Preoperative atorvastatin therapy to decrease the systemic inflammatory response after coronary artery bypass grafting. J Int Med Res. 2008;36:1248-1254.
19. Farooq V, Serruys PW, Bourantas C, et al. Incidence and multivariable correlates of long-term mortality in patients treated with surgical or percutaneous revascularization in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) trial. Eur Heart J. 2012;33:3105-3113.
20. Ferguson TBJr, Coombs LP, Peterson ED; Society of Thoracic Surgeons National Adult Cardiac Surgery Database. Preoperative beta-blocker use and mortality and morbidity following CABG surgery in North America. JAMA. 2002;287:2221-2227.
21. Foody JM, Ferdinand FD, Pearce GL, et al. HDL cholesterol level predicts survival in men after coronary artery bypass graft surgery: 20-year experience from The Cleveland Clinic Foundation. Circulation. 2000;102 (Suppl. 3):III90-III94.
22. Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation. 2004;110:1202-1208.
23. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730-1737.
24. Fremes S.E, Levinton C, Naylor C.D, et al. Optimal antithrombotic therapy following aortocoronary bypass: a metaanalysis. Eur J Cardiothorac Surg. 1993;7:169-180.
25. Frick MH, Syvanne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol: Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation. 1997;96:2137-2143.
26. Gallagher R, McKinley S. Anxiety, depression and perceived control in patients having coronary artery bypass grafts. J Adv Nurs. 2009;65:2386-2396.
27. Gao C, Ren C, Li D, Li L. Clopidogrel and aspirin versus clopidogrel alone on graft patency after coronary artery bypass grafting. Ann Thorac Surg. 2009;88:59-62.
28. Gohlke H, Gohlke-Barwolf C, Sturzenhofecker P, et al. Improved graft patency with anticoagulant therapy after aortocoronary bypass surgery: a prospective, randomized study. Circulation. 1981;64 (Pt. 2):II22-II27.
29. Goldman S, Copeland J, Moritz T, et al. Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation. 1989;80:1190-1197.
30. Hata M, Takayama T, Sezai A, et al. Efficacy of aggressive lipid controlling therapy for preventing saphenous vein graft disease. Ann Thorac Surg. 2009;88:1440-1444.
31. Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011;57:672-684.
32. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo- controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279-1291.
33. Huffmyer JL, Mauermann WJ, Thiele RH, et al. Preoperative statin administration is associated with lower mortality and decreased need for postoperative hemodialysis in patients undergoing coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2009;23:468-473.
34. Jensen BO, Rasmussen LS, Steinbruchel DA. Cognitive outcomes in elderly high-risk patients 1 year after off-pump versus on-pump coronary artery bypass grafting: a randomized trial. Eur J Cardiothorac Surg. 2008;34:1016-1021.
35. Johnson WD, Kayser KL, Hartz AJ, Saedi SF. Aspirin use and survival after coronary bypass surgery. Am Heart J. 1992;123:603-608.
36. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-1861.
37. Khan MF, Wendel CS, Movahed MR. Prevention of post-coronary artery bypass grafting (CABG) atrial fibrillation: efficacy of prophylactic beta-blockers in the modern era: a meta-analysis of latest randomized controlled trials. Ann Noninvasive Electrocardiol. 2013;18:58-68.
38. Kim DH, Daskalakis C, Silvestry SC, et al. Aspirin and clopidogrel use in the early postoperative period following on-pump and off-pump coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2009;138:1377-1384.
39. Kulik A, Ruel M, Jneid H, et al. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. Circulation. 2015;131:927-964.
40. Kulik A, Voisine P, Mathieu P, et al. Statin therapy and saphenous vein graft disease after coronary bypass surgery: analysis from the CASCADE randomized trial. Ann Thorac Surg. 2011;92:1284-1290.
41. Liakopoulos OJ, Choi YH, Haldenwang PL, et al. Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30,000 patients. Eur Heart J. 2008;29:1548-1559.
42. Liakopoulos OJ, Choi YH, Kuhn EW, et al. Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review. J Thorac Cardiovasc Surg. 2009;138:678-686.
43. Lim E, Ali Z, Ali A, et al. Indirect comparison meta-analysis of aspirin therapy after coronary surgery. Brit Med. J. 2003;327:1309.
44. Lindsay GM, Tolmie EP, Martin WM, et al. Smoking after coronary artery bypass: high three-year mortality. Thorac Cardiovasc Surg. 2009;57:135-140.
45. Mangano DT; Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. New Engl J Med. 2002;347:1309-1317.
46. Mannacio VA, Di Tommaso L, Antignan A, et al. Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study. Heart. 2012;98:1710-1715.
47. McEnany MT, Salzman EW, Mundth ED, et al. The effect of antithrombotic therapy on patency rates of saphenous vein coronary artery bypass grafts. J. Thorac Cardiovasc Surg. 1982;83:81-89.
48. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin- converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-771.
49. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297:499-508.
50. Nocerino AG, Achenbach S, Taylor AJ. Meta-analysis of effect of single versus dual antiplatelet therapy on early patency of bypass conduits after coronary artery bypass grafting. Am J Cardiol. 2013;112:1576-1579.
51. Ouattara A, Benhaoua H, Le Manach Y, et al. Perioperative statin therapy is associated with a significant and dose-dependent reduction of adverse cardiovascular outcomes after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2009;23:633-638.
52. Pantely GA, Goodnight SH. Jr, Rahimtoola SH, et al. Failure of antiplatelet and anticoagulant therapy to improve patency of grafts after coronary-artery bypass: a controlled randomized study. New Engl J Med. 1979;301:962-966.
53. Papathanasiou A, Milionis H, Toumpoulis I, et al. Smoking cessation is associated with reduced long-term mortality and the need for repeat interventions after coronary artery bypass grafting. Eur J Cardiovasc Prev Rehabil. 2007;14:448-450.
54. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. New Engl J Med. 1999;341:709-717.
55. Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and lowdose anticoagulation on obstructive changes in saphenous-vein coronaryartery bypass grafts. New Engl J Med. 1997;336:153-162.
56. Pound EM, Kang JX, Leaf A. Partitioning of polyunsaturated fatty acids, which prevent cardiac arrhythmias, into phospholipid cell membranes. J Lipid Res. 2001;42:346-351.
57. Puskas JD, Williams WH, Mahoney EM, et al. Off-pump vs conventional coronary artery bypass grafting: early and 1-year graft patency, cost, and quality-of-life outcomes: a randomized trial. JAMA. 2004;291:1841-1849.
58. Rouleau JL, Warnica WJ, Baillot R, et al. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation. 2008;117:24-31.
59. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. New Engl J Med. 1999;341:410-418.
60. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation. 2001;104:1985-1991.
61. Shah SJ, Waters DD, Barter P, et al. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. J Am Coll Cardiol. 2008;51:1938-1943.
62. Smith PK, Goodnough LT, Levy JH, et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol. 2012;60:388-396.
63. Sorensen R, Abildstrom SZ, Hansen PR, et al. Efficacy of post-operative clopidogrel treatment in patients revascularized with coronary artery bypass grafting after myocardial infarction. J Am Coll Cardiol. 2011;57:1202-1209.
64. Van Domburg RT, Meeter K, van Berkel DF, et al. Smoking cessation reduces mortality after coronary artery bypass surgery: a 20-year follow-up study. J Am Coll Cardiol. 2000;36:878-883.
65. Wang Z, Gao F, Men J, et al. Aspirin resistance in off-pump coronary artery bypass grafting. Eur J Cardiothorac Surg. 2012;41:108-112.
66. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. New Engl J Med. 2011;364:11-21.
67. Zimmermann N, Kienzle P, Weber AA, et al. Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2001;121:982-984.

Almanac 2014: aortic valve disease

С.M. Otto 

References 

1. Abdel-Wahab M, Zahn R, Gerckens U, et al. Predictors of 1-year mortality in patients with aortic regurgitation after transcatheter aortic valve implantation: an analysis from the multicentre German TAVI registry. Heart 2014;100:1250–6.
2. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 2014;370:1790–8.
3. Ali OA, Chapman M, Nguyen TH, et al. Interactions between inflammatory activation and endothelial dysfunction selectively modulate valve disease progression in patients with bicuspid aortic valve. Heart 2014;100:800–5.
4. Aung N, Dworakowski R, Byrne J, et al. Progressive rise in red cell distribution width is associated with poor outcome after transcatheter aortic valve implantation. Heart 2013;99:1261–6.
5. Barreto-Filho JA, Wang Y, Dodson JA, et al. Trends in aortic valve replacement for elderly patients in the United States, 1999–2011. JAMA 2013;310:2078–85.
6. Borz B, Durand E, Godin M, et al. Incidence, predictors and impact of bleeding after transcatheter aortic valve implantation using the balloon-expandable Edwards prosthesis. Heart 2013;99:860–5.
7. Chambers JB, Ray S, Prendergast B, et al. Specialist valve clinics: recommendations from the British Heart Valve Society working group on improving quality in the delivery of care for patients with heart valve disease. Heart 2013;99:1714–16.
8. Chiang YP, Chikwe J, Moskowitz AJ, et al. Survival and long-term outcomes following bioprosthetic vs mechanical aortic valve replacement in patients aged 50 to 69 years. JAMA 2014;312:1323–9.
9. Cimadevilla C, Cueff C, Hekimian G, et al. Prognostic value of B-type natriuretic peptide in elderly patients with aortic valve stenosis: the COFRASA-GENERAC study. Heart 2013;99:461–7.
10. Detaint D, Michelena HI, Nkomo VT, et al. Aortic dilatation patterns and rates in adults with bicuspid aortic valves: a comparative study with Marfan syndrome and degenerative aortopathy. Heart 2014;100:126–34.
11. Du DT, McKean S, Kelman JA, et al. Early mortality after aortic valve replacement with mechanical prosthetic vs bioprosthetic valves among medicare beneficiaries: a population-based cohort study. JAMA Intern Med 2014;174:1788–95.
12. Dvir D, Webb JG, Bleiziffer S, et al. Valve-in-Valve International Data Registry Investigators. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA 2014;312:162–70.
13. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. NEnglJ Med 2013;369:1206–14.
14. Eleid MF, Forde I, Edwards WD, et al. Type A aortic dissection in patients with bicuspid aortic valves: clinical and pathological comparison with tricuspid aortic valves. Heart 2013;99:1668–74.
15. Eveborn GW, Schirmer H, Heggelund G, et al. The evolving epidemiology of valvular aortic stenosis. The Tromso study. Heart 2013;99:396–400.
16. Fairbairn TA, Meads DM, Hulme C, et al. The cost-effectiveness of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis at high operative risk. Heart 2013;99:914–20.
17. Fairbairn TA, Steadman CD, Mather AN, et al. Assessment of valve haemodynamics, reverse ventricular remodelling and myocardial fibrosis following transcatheter aortic valve implantation compared to surgical aortic valve replacement: a cardiovascular magnetic resonance study. Heart 2013;99:1185–91.
18. Greif M, Lange P, Nabauer M, et al. Transcutaneous aortic valve replacement with the Edwards SAPIEN XT and Medtronic CoreValve prosthesis under fluoroscopic guidance and local anaesthesia only. Heart 2014;100:691–5.
19. Iung B, Laouenan C, Himbert D, et al. Predictive factors of early mortality after transcatheter aortic valve implantation: individual risk assessment using a simple score. Heart 2014;100:1016–23.
20. Jander N, Gohlke-Barwolf C, Bahlmann E, et al. Indexing aortic valve area by body surface area increases the prevalence of severe aortic stenosis. Heart 2014;100:28–33.
21. Jander N, Hochholzer W, Kaufmann BA, et al. Velocity ratio predicts outcomes in patients with low gradient severe aortic stenosis and preserved EF. Heart 2014;100:1946–53.
22. Kalsch H, Lehmann N, Mahabadi AA, et al. Investigator Group of the Heinz Nixdorf Recall Study. Beyond Framingham risk factors and coronary calcification: does aortic valve calcification improve risk prediction? The Heinz Nixdorf Recall Study. Heart 2014;100:930–7.
23. Khawaja MZ, Williams R, Hung J, et al. Impact of preprocedural mitral regurgitation upon mortality after transcatheter aortic valve implantation (TAVI) for severe aortic stenosis. Heart 2014;100:1799–803.
24. Mack MJ, Brennan JM, Brindis R, et al. Outcomes following transcatheter aortic valve replacement in the United States. JAMA 2013;310:2069–77.
25. Minners J, Gohlke-Baerwolf C, Kaufmann BA, et al. Adjusting parameters of aortic valve stenosis severity by body size. Heart 2014;100:1024–30.
26. Mylotte D, Lange R, Martucci G, et al. Transcatheter heart valve implantation for failing surgical bioprostheses: technical considerations and evidence for valve-in-valve procedures. Heart 2013;99:960–7.
27. Nishimura RA, Otto CM, Bonow RO, et al. American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2438–88.
28. Otto CM and Prendergast B. Aortic-valve stenosis—from patients at risk to severe valve obstruction. N Engl J Med 2014;371:744–56.
29. Otto CM. New ACC/AHA valve guidelines: aligning defintions of aortic stenosis severity with treatment recommendations. Heart 2014;100:902–4.
30. Pibarot P. Aortic stenosis: flow matters. Heart 2015;101:5–6.
31. Price J, Toeg H, Lam BK, et al. The impact of prosthesis-patient mismatch after aortic valve replacement varies according to age at operation. Heart 2014;100:1099–106.
32. Ribeiro HB and Rodes-Cabau J. The multiparametric FRANCE-2 risk score: one step further in improving the clinical decision-making process in transcatheter aortic valve implantation. Heart 2014;100:993–5.
33. Shavelle DM. The evolution of transcutaneous aortic valve replacement: moving in the right direction. Heart 2014;100:683–4.
34. Smith JG, Luk K, Schulz CA, et al., Cohorts for H and Aging Research in Genetic Epidemiology Extracoronary Calcium Working Group. Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. JAMA 2014;312:1764–71.
35. Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013;368:503–12.
36. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012;33:2451–96.

Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: The EFFORT Study

А. Briasoulis, R. Oliva, R. Kalaitzidis, C. Flynn, I. Lazich, C. Schlaffer, G. Bakris 

References